{"schema_version":"secwatch.filing_event.v1","accession":"0001129928-26-000024","form_type":"8-K","ticker":"ONCY","cik":"0001129928","company_name":"ONCOLYTICS BIOTECH INC","filed_at":"2026-04-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:31.988492+00:00","generated_at":"2026-05-15T07:14:04.856288+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Oncolytics schedules Type C FDA meeting for pelareorep single-arm study in anal cancer","bullets":["FDA meeting set for April 16, 2026 to discuss single-arm pivotal study of pelareorep + checkpoint inhibitor in SCAC.","Proposed enrollment of 60-70 second-line+ patients with no approved therapy; primary endpoint ORR for full approval.","GOBLET Cohort 4 achieved ~30% ORR and median DOR of 17 months vs real-world 10-14% ORR and 9.5 months DOR.","SCAC is a rare cancer with ~54,000 annual global cases; anal cancer market projected to reach $2.3B by 2035."],"urls":{"canonical":"https://secwatch.observer/filing/0001129928-26-000024","json":"https://secwatch.observer/filing/0001129928-26-000024.json","markdown":"https://secwatch.observer/filing/0001129928-26-000024.md","text":"https://secwatch.observer/filing/0001129928-26-000024.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1129928/000112992826000024/0001129928-26-000024-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1129928/000112992826000024/oncy-20260406.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T07:14:04.856288+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"comparable_filings":[{"accession":"0001108426-26-000030","ticker":"TXNM","company_name":"TXNM ENERGY INC","filed_at":"2026-06-01T21:54:12+00:00","headline":"TXNM subsidiaries: TNMP rate settlement with $20.5M storm rider, PNM resource plan with 1.65 GW renewables","event_type":"regulatory","sec_items":["7.01","8.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same SEC item: 8.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001108426-26-000030","json":"https://secwatch.observer/filing/0001108426-26-000030.json","markdown":"https://secwatch.observer/filing/0001108426-26-000030.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1108426/000110842626000030/0001108426-26-000030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/22767/000110842626000030/pnm-20260601.htm"},"side_by_side_evidence":null},{"accession":"0001628280-26-039424","ticker":"RICK","company_name":"RCI HOSPITALITY HOLDINGS, INC.","filed_at":"2026-06-01T19:08:52+00:00","headline":"RCI Hospitality regains Nasdaq compliance after filing delayed Q1 10-Q","event_type":"regulatory","sec_items":["8.01","9.01"],"materiality_score":0.5,"calibrated_materiality_score":0.5,"match_reasons":["same SEC item: 8.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-039424","json":"https://secwatch.observer/filing/0001628280-26-039424.json","markdown":"https://secwatch.observer/filing/0001628280-26-039424.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/935419/000162828026039424/0001628280-26-039424-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/935419/000162828026039424/rick-20260529.htm"},"side_by_side_evidence":null},{"accession":"0001178913-26-002988","ticker":"SLXN","company_name":"Silexion Therapeutics Corp","filed_at":"2026-05-29T11:00:25+00:00","headline":"Silexion Therapeutics completes 1-for-10 reverse share split; warrants adjusted","event_type":"regulatory","sec_items":["3.03","5.03","8.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same SEC item: 8.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-26-002988","json":"https://secwatch.observer/filing/0001178913-26-002988.json","markdown":"https://secwatch.observer/filing/0001178913-26-002988.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326002988/0001178913-26-002988-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326002988/zk2635442.htm"},"side_by_side_evidence":null},{"accession":"0001193125-26-240645","ticker":"JAGX","company_name":"Jaguar Health, Inc.","filed_at":"2026-05-27T13:10:06+00:00","headline":"Jaguar Health regains Nasdaq Bid Price compliance; monitoring until May 2027","event_type":"regulatory","sec_items":["7.01","8.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same SEC item: 8.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-240645","json":"https://secwatch.observer/filing/0001193125-26-240645.json","markdown":"https://secwatch.observer/filing/0001193125-26-240645.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526240645/0001193125-26-240645-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526240645/d129501d8k.htm"},"side_by_side_evidence":null},{"accession":"0001493152-26-025171","ticker":"MBOT","company_name":"Microbot Medical Inc.","filed_at":"2026-05-26T12:30:22+00:00","headline":"Microbot Medical receives Israeli regulatory approval for LIBERTY System, first outside U.S.","event_type":"regulatory","sec_items":["7.01","8.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same SEC item: 8.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-025171","json":"https://secwatch.observer/filing/0001493152-26-025171.json","markdown":"https://secwatch.observer/filing/0001493152-26-025171.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/883975/000149315226025171/0001493152-26-025171-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/883975/000149315226025171/form8-k.htm"},"side_by_side_evidence":null},{"accession":"0001731122-26-000781","ticker":"AVXL","company_name":"ANAVEX LIFE SCIENCES CORP.","filed_at":"2026-05-22T12:15:26+00:00","headline":"Anavex receives Nasdaq delinquency notice for late 10-Q filing; deadline July 20, 2026","event_type":"regulatory","sec_items":["3.01","8.01","9.01"],"materiality_score":0.55,"calibrated_materiality_score":0.55,"match_reasons":["same SEC item: 8.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001731122-26-000781","json":"https://secwatch.observer/filing/0001731122-26-000781.json","markdown":"https://secwatch.observer/filing/0001731122-26-000781.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1314052/000173112226000781/0001731122-26-000781-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1314052/000173112226000781/e7667_8-k.htm"},"side_by_side_evidence":null},{"accession":"0001104659-26-065180","ticker":"ADGM","company_name":"Adagio Medical Holdings, Inc.","filed_at":"2026-05-21T20:31:34+00:00","headline":"Adagio submits PMA to FDA for vCLAS VT ablation system; trial shows 97.4% acute success","event_type":"regulatory","sec_items":["8.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same SEC item: 8.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-065180","json":"https://secwatch.observer/filing/0001104659-26-065180.json","markdown":"https://secwatch.observer/filing/0001104659-26-065180.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2006986/000110465926065180/0001104659-26-065180-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2006986/000110465926065180/tm2614299d2_8k.htm"},"side_by_side_evidence":null},{"accession":"0001104659-26-064863","ticker":"CGTX","company_name":"COGNITION THERAPEUTICS INC","filed_at":"2026-05-21T11:34:37+00:00","headline":"Cognition Therapeutics completes productive FDA meeting for zervimesine in DLB psychosis","event_type":"regulatory","sec_items":["8.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same SEC item: 8.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-064863","json":"https://secwatch.observer/filing/0001104659-26-064863.json","markdown":"https://secwatch.observer/filing/0001104659-26-064863.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1455365/000110465926064863/0001104659-26-064863-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1455365/000110465926064863/tm2615260d1_8k.htm"},"side_by_side_evidence":null}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}